Document is current
Any future updates will be listed below
-
Authors
Kychygina, Anna https://orcid.org/0000-0002-1971-2812
Cassagne, Myriam https://orcid.org/0000-0002-7554-661X
Tauber, Marie https://orcid.org/0000-0001-6245-7442
Galiacy, Stéphane
Paul, Carle https://orcid.org/0000-0003-0165-5263
Fournié, Pierre https://orcid.org/0000-0002-9224-2351
Simon, Michel https://orcid.org/0000-0003-3655-6329
-
Funding
Funding for this research was provided by:
Société Française de Dermatologie et de Pathologie Sexuellement Transmissible
- License Information
-
More Information
Article History
Accepted: 3 March 2022
First Online: 11 March 2022
Declarations
:
: AK, MC, PF, SG, and MS declare no conflicts of interest. MT is an investigator for AbbVie, Boehringer Engelheim, Eli Lilly, Galderma, LEO Pharma, Pierre Fabre, and Sanofi–Regeneron and a consultant or member of the advisory board for Sanofi–Regeneron. CP is an investigator or consultant for AbbVie, Astellas, Eli Lilly, LEO Pharma, Pierre Fabre, and Regeneron and Sanofi.
